Christian Buske, Jorge J Castillo, Jithma Prasad Abeykoon, Ranjana Advani, Suzanne O Arulogun, Andrew R Branagan, Xinxin Cao, Shirley D'Sa, Jian Hou, Prashant Kapoor, Efstathios Kastritis, Marie J Kersten, Veronique LeBlond, Merav Leiba, Jeffrey V Matous, Jonas Paludo, Lugui Qiu, Constantine S Tam, Alessandra Tedeschi, Sheeba K Thomas, Ibrahim Tohidi-Esfahani, Marzia Varettoni, Josephine M Vos, Ramon Garcia-Sanz, Jesus San-Miguel, Meletios A Dimopoulos, Steven P Treon, Judith Trotman
Consensus Panel 1 (CP1) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naïve patients with WM. The panel reiterated that watchful waiting remains the gold standard for asymptomatic patients without critically elevated IgM or compromised hematopoietic function. For first-line treatment, chemoimmunotherapy (CIT) regimens such as dexamethasone, cyclophosphamide, rituximab (DRC), or bendamustine, rituximab (Benda-R) continue to play a central role in managing WM, as they are effective, of fixed duration, generally well-tolerated, and affordable...
March 29, 2023: Seminars in Hematology